MAM
VERV

Martingale Asset Management’s Verve Therapeutics VERV Stock Holding History

Martingale Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,350
Closed -$565K – 849
2025
Q2 		$565K Sell
50,350
-69
-0.1% -$393 0.01% 596
2025
Q1 		$230K Sell
50,419
-3
-0% -$20 0.01% 719
2024
Q4 		$284K Sell
50,422
-15
-0% -$85 0.01% 697
2024
Q3 		$244K Hold
50,437
– – 0.01% 740
2024
Q2 		$246K Buy
50,437
+21,430
+74% +$135K 0.01% 724
2024
Q1 		$385K Buy
29,007
+805
+3% +$10.7K 0.01% 663
2023
Q4 		$393K Buy
28,202
+7,785
+38% +$96.5K 0.01% 655
2023
Q3 		$271K Buy
+20,417
New +$329K 0.01% 704
2023
Q2 		– Sell
-16,273
Closed -$235K – 879
2023
Q1 		$235K Hold
16,273
– – ﹤0.01% 748
2022
Q4 		$315K Hold
16,273
– – 0.01% 715
2022
Q3 		$559K Buy
+16,273
New +$519K 0.01% 597

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Martingale Asset Management's VERV Position: Q3 2025 in Review

Martingale Asset Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 50,350 shares — an estimated $565K sold.

Martingale Asset Management first reported a position in VERV in Q3 2022 and held it in 11 quarters. The position peaked at $565K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Martingale Asset Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Martingale Asset Management sold 50,350 Verve Therapeutics shares in Q3 2025, an estimated $565K.
  • Martingale Asset Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 11 quarters.
  • Martingale Asset Management's Verve Therapeutics position peaked at $565K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Martingale Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.